Search results
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Zacks· 6 days agoThe Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has gained 8.3% over this period. Now the key question is: Where could the stock be headed in ...
How To Know If Gilead Sciences, Inc.
Marketing Sentinel· 2 days agoCompany’s recent per share price level of $65.68 trading at -$0.49 or -0.74% at ring of the bell on the day assigns it a market valuation of $81.83B. That closing
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today - Gilead Sciences (NASDAQ:GILD)
Benzinga· 6 days agoGilead Sciences GILD has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return of 11.12%. Currently, Gilead Sciences ...
BMO maintains price target on Gilead stock amid oncology push By Investing.com
Investing.com· 4 days agoOn Thursday, BMO Capital Markets sustained its positive stance on Gilead Sciences (NASDAQ:GILD),...
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by King Luther Capital Management Corp
ETF DAILY NEWS· 3 days ago(NASDAQ:GILD – Free Report) by 4.6% in the fourth quarter, according to its most recent Form 13F filing with the...Securities and Exchange Commission. The institutional investor ...
Brown Advisory Inc. Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 6 days agoBrown Advisory Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned ...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks via Yahoo Finance· 7 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in...
Investing in Gilead Sciences, Inc.
Knox Daily· 6 days agoDeutsche Bank started covering the stock on November 09, 2023. It rated GILD as “a Hold”. Price Performance Review of GILD< ...
Notable Wall Street bear tweaks S&P 500 forecast after record rally
TheStreet.com· 7 days agoWith 93% of S&P 500 companies having reported first-quarter earnings, a blend of their results and analyst forecasts for the remaining companies shows a profit increase of 5.7% from a year earlier ...
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And...
Benzinga via Yahoo Finance· 7 days agoSaturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay...
